120 / 144
120
PERGUNTAS & RESPOSTAS
EMD
- Edema Macular Diabético
Referências
1. Tham YC, Cheng CY. Associations between chronic systemic diseases and primary
open angle glaucoma: an epidemiological perspective. Clin Experiment Ophthalmol.
2017;45(1):24-32.
2. Horwitz A, Petrovski BÉ, Torp-Pedersen C, et al. Danish Nationwide Data Reveal a Link
between Diabetes Mellitus, Diabetic Retinopathy, and Glaucoma. J Diabetes Res. Hin-
dawi Publishing Corporation; 2016;2016:13-5.
3. Yannuzzi NA, Patel SN, Bhavsar KV, et al. Predictors of sustained intraocular pressure
elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am
J Ophthalmol. 2014;158:319-27.e2.
4. Dedania VS, Bakri SJ. Sustained Elevation Of Intraocular Pressure After Intravitreal Anti-
-Vegf Agents: What Is the Evidence? Retina. 2015;35(5):841-58.
5. Aref AA. Management of immediate and sustained intraocular pressure rise associated
with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin
Ophthalmol. 2012;23(2):105-10.
6. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pres-
sure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina.
2013;33(1):179-87.
7. Eadie BD, Etminan M, Carleton BC, et al. Association of Repeated Intravitreous Bevacizu-
mab Injections With Risk for Glaucoma Surgery. JAMA Ophthalmol [Internet]. 2017:1-6.
8. Bressler SB, Almukhtar T, Bhorade A, et al. Repeated Intravitreous Ranibizumab Injections
for Diabetic Macular Edema and the Risk of Sustained IOP Elevation or Ocular Hypoten-
sive Treatment. JAMA Ophthalmol. 2016;133(5):1064-77.
9. Maturi RK, Pollack A, Uy HS, et al. Intraocular Pressure in Patients With Diabetic Macular
Edema Treated With Dexamethasone Intravitreal Implant in the 3-Year Mead Study. Reti-
na. 2016;36(6):1143-52.
10. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery `uocinolone acetonide
vitreous inserts provide bene%t for at least 3 years in patients with diabetic macular ede-
ma. Ophthalmology. 2012;119(10):2125-32.
11. Lee JW, Park H, Choi JH, et al. Short-term changes of intraocular pressure and ocular per-
fusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthal-
mology. 2016;16(1):69.
12. Kim G-N, Han Y-S, Chung I-Y, et al. Effect of Dorzolamide/Timolol or Brinzolamide/Timo-
lol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension.
Semin Ophthalmol, 2013;28(2):61–7.
13. El Chehab H, Le Corre A, Agard E, et al. Effect of topical pressure-lowering medication
on prevention of intraocular pressure spikes after intravitreal injection. Eur J Ophthalmol.
2013;23(3):277–83.
14. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal Bevacizumab to Treat Iris Neo-
vascularization and Neovascular Glaucoma Secondary to Ischemic Retinal Diseases in 41
Consecutive Cases. Ophthalmology. 2008;115(9): 1571-80, 1580.e1-3.
15. Kim M, Lee C, Payne R, et al. Angiogenesis in Glaucoma Filtration Surgery and Neovas-
cular Glaucoma-A Review. Surv Ophthalmol, 2015;60(6):524-35.
16. Gross JG, Glassman AR, Jampol LM, et al. Panretinal Photocoagulation vs Intravitreous
Ranibizumab for Proliferative Diabetic Retinopathy. Jama, 2015;314(20):2137.
17. Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical ef%cacy of intravitreal a`iber-
cept versus panretinal photocoagulation for best corrected visual acuity in patients with
proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded,
randomised, controlled, phase 2b, non-inferiority trial. Lancet, 2017;2193–203.